Literature DB >> 9167746

Tumor markers in the diagnosis of malignant serous effusions.

S Cascinu1, E Del Ferro, I Barbanti, M Ligi, A Fedeli, G Catalano.   

Abstract

To assess the possibility of increasing the detection rates of cytological examination in malignant effusions by the selection of specific tumor markers for a given type of tumor, we measured CEA, CA 19.9, CA 15.3, MCA, PSA, and AFP in malignant effusions from 89 patients with the following primary malignancies: colon, stomach, breast, liver, prostate, lung, and kidney. Cytological examination was positive in only 35 of 89 patients (40%), while the tumor markers were positive in 72 of 89 cases (80%). However, apart from small cell lung and kidney cancers, where the lack of a specific tumor marker resulted in no advantage, in the other types of tumors, the specific marker for each tumor identified correctly malignant effusions in 72 of 74 cases (97%). In fact, CEA was positive in 11 of 11 effusions induced by colorectal cancer; CA 19.9 in 28 of 30 gastric cancer effusions, while MCA and CA 15.3 were positive in breast cancer effusions (16/22 and 20/22). Finally, elevated AFP and PSA indicated hepatocellular and prostate cancer, respectively. In conclusion, in cancer patients with elevated effusion levels of specific tumor markers, the effusions could be considered of a malignant nature even without cytologically demonstrable tumor cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9167746     DOI: 10.1097/00000421-199706000-00007

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  10 in total

1.  Discrimination between malignant and nonmalignant ascites using serum and ascitic fluid proteins in a multivariate analysis model.

Authors:  M G Alexandrakis; J A Moschandrea; S A Koulocheri; E Kouroumalis; G D Eliopoulos
Journal:  Dig Dis Sci       Date:  2000-03       Impact factor: 3.199

2.  Value of carcinoembryonic antigen (CEA) and cholesterol assays of ascitic fluid in cases of inconclusive cytology.

Authors:  M Gulyás; A D Kaposi; G Elek; L G Szollár; A Hjerpe
Journal:  J Clin Pathol       Date:  2001-11       Impact factor: 3.411

3.  High level of CA19-9, CA50, and CEA-producible human cholangiocarcinoma cell line changes in the secretion ratios in vitro or in vivo.

Authors:  M Watanabe; M Chigusa; H Takahashi; J Nakamura; H Tanaka; T Ohno
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-02       Impact factor: 2.416

Review 4.  [Treatment of malignant pericardial effusion].

Authors:  M Berg; A Heisel; D Ukena; H J Schäfers; H Schieffer
Journal:  Med Klin (Munich)       Date:  1997-12

5.  Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions.

Authors:  M Miédougé; P Rouzaud; G Salama; M C Pujazon; C Vincent; M A Mauduyt; J Reyre; P Carles; G Serre
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

6.  Malignant pleural effusion from prostate adenocarcinoma.

Authors:  James C Knight; Malia A Ray; Sadia Benzaquen
Journal:  Respir Med Case Rep       Date:  2014-08-01

7.  Clinical diagnostic utility of CA 15-3 for the diagnosis of malignant pleural effusion: A meta-analysis.

Authors:  Qiang Wu; Min Li; Shu Zhang; Lu Chen; Xingting Gu; Feng Xu
Journal:  Exp Ther Med       Date:  2014-10-30       Impact factor: 2.447

8.  Guidelines on the management of ascites in cirrhosis.

Authors:  Guruprasad P Aithal; Naaventhan Palaniyappan; Louise China; Suvi Härmälä; Lucia Macken; Jennifer M Ryan; Emilie A Wilkes; Kevin Moore; Joanna A Leithead; Peter C Hayes; Alastair J O'Brien; Sumita Verma
Journal:  Gut       Date:  2020-10-16       Impact factor: 23.059

9.  Evaluation of malignant effusions using MR-based T1 mapping.

Authors:  A Sprinkart; F Kütting; D Kuetting; J Luetkens; A Faron; A Isaak; U Attenberger; C C Pieper; L Meffert; C Jansen
Journal:  Sci Rep       Date:  2021-03-29       Impact factor: 4.379

10.  Vascular endothelial growth factor levels in ascites between chemonaive and chemotreated patients.

Authors:  Hae Kyung Lee; Hiun Suk Chae; Jin Soo Kim; Hyung Keun Kim; Young Seok Cho; Sang Young Rho; Jin-Hyoung Kang; Seok Goo Cho; Hong Seok Jang; Kyungja Han
Journal:  Yonsei Med J       Date:  2008-06-30       Impact factor: 2.759

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.